{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:08:46Z","timestamp":1790824126343,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T00:00:00Z","timestamp":1426204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T00:00:00Z","timestamp":1426204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Schisandrin B (SchB) is one of the most abundant bioactive dibenzocyclooctadiene derivatives found in the fruit of <jats:italic>Schisandra chinensis<\/jats:italic>. Here, we investigated the potential therapeutic effects of SchB on non-alcoholic fatty-liver disease (NAFLD). In lipidomic study, ingenuity pathway analysis highlighted palmitate biosynthesis metabolic pathway in the liver samples of SchB-treated high-fat-diet-fed mice. Further experiments showed that the SchB treatment reduced expression and activity of fatty acid synthase, expressions of hepatic mature sterol regulatory element binding protein-1 and tumor necrosis factor-\u03b1 and hepatic level of palmitic acid which is known to promote progression of steatosis to steatohepatitis. Furthermore, the treatment also reduced hepatic fibrosis, activated nuclear factor-erythroid-2-related factor-2 which is known to attenuate the progression of NASH-related fibrosis. Interestingly, in fasting mice, a single high-dose SchB induced transient lipolysis and increased the expressions of adipose triglyceride lipase and phospho-hormone sensitive lipase. The treatment also increased plasma cholesterol levels and 3-hydroxy-3-methylglutaryl-CoA reductase activity, reduced the hepatic low-density-lipoprotein receptor expression in these mice. Our data not only suggest SchB is a potential therapeutic agent for NAFLD, but also provided important information for a safe consumption of SchB because SchB overdosed under fasting condition will have adverse effects on lipid metabolism.<\/jats:p>","DOI":"10.1038\/srep09114","type":"journal-article","created":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T10:51:34Z","timestamp":1426243894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers"],"prefix":"10.1038","volume":"5","author":[{"given":"Hiu Yee","family":"Kwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiejun","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Leung","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Chung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqiong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anfernee Kai Wing","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang Fun","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ling","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,13]]},"reference":[{"key":"BFsrep09114_CR1","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/hep.510300604","volume":"30","author":"P Angulo","year":"1999","unstructured":"Angulo, P. et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30, 1356\u20131362 (1999).","journal-title":"Hepatology"},{"key":"BFsrep09114_CR2","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/hep.21391","volume":"44","author":"V Ratziu","year":"2006","unstructured":"Ratziu, V. & Poynard, T. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology 44, 802\u2013805 (2006).","journal-title":"Hepatology"},{"key":"BFsrep09114_CR3","unstructured":"LaBrecque, D. et al. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. World Gastroenterology Organization Global Guidelines [1\u201329] (World Gastroenterology Organisation, 2012)."},{"key":"BFsrep09114_CR4","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1055\/s-0028-1091984","volume":"28","author":"MR Kashi","year":"2008","unstructured":"Kashi, M. R. et al. Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis 28, 396\u2013406 (2008).","journal-title":"Semin Liver Dis"},{"key":"BFsrep09114_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1365-2036.2004.02025.x","volume":"20","author":"S Nair","year":"2004","unstructured":"Nair, S. et al. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 20, 23\u201328 (2004).","journal-title":"Aliment Pharmacol Ther"},{"key":"BFsrep09114_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14740330802597821","volume":"8","author":"CV Rizos","year":"2009","unstructured":"Rizos, C. V. et al. How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf 8, 15\u201332 (2009).","journal-title":"Expert Opin Drug Saf"},{"key":"BFsrep09114_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.plipres.2012.10.004","volume":"52","author":"AK Leamy","year":"2013","unstructured":"Leamy, A. K. et al. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res 52, 165\u2013174 (2013).","journal-title":"Prog Lipid Res"},{"key":"BFsrep09114_CR8","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jnutbio.2007.10.001","volume":"19","author":"CL Gentile","year":"2008","unstructured":"Gentile, C. L. & Paqliassotti, M. J. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem 19, 567\u2013576 (2008).","journal-title":"J Nutr Biochem"},{"key":"BFsrep09114_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-511X-11-1","volume":"11","author":"Y Zhang","year":"2012","unstructured":"Zhang, Y. et al. Palmitic and linoleic acids induce ER stress and apoptosis in hepatoma cells. Lipids Health Dis 11, 1 (2012).","journal-title":"Lipids Health Dis"},{"key":"BFsrep09114_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2217\/clp.09.85","volume":"5","author":"SC Cazanave","year":"2010","unstructured":"Cazanave, S. C. & Gores, G. J. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol 5, 71\u201385 (2010).","journal-title":"Clin Lipidol"},{"key":"BFsrep09114_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0016-5085(03)80183-X","volume":"125","author":"AE Feldstein","year":"2003","unstructured":"Feldstein, A. E. et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125, 37\u201343 (2003).","journal-title":"Gastroenterology"},{"key":"BFsrep09114_CR12","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1073\/pnas.91.14.6379","volume":"91","author":"FP Kuhajda","year":"1994","unstructured":"Kuhajda, F. P. et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A 91, 6379\u201383 (1994).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFsrep09114_CR13","first-page":"351","volume":"20","author":"M Kohjima","year":"2007","unstructured":"Kohjima, M. et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 20, 351\u2013358 (2007).","journal-title":"Int J Mol Med"},{"key":"BFsrep09114_CR14","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.metabol.2014.04.003","volume":"63","author":"F Ameer","year":"2014","unstructured":"Ameer, F. et al. De novo lipogenesis in health and disease. Metabolism 63, 895\u2013902 (2014).","journal-title":"Metabolism"},{"key":"BFsrep09114_CR15","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1002\/hep.23229","volume":"50","author":"P Puri","year":"2009","unstructured":"Puri, P. et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 50, 1827\u20131838 (2009).","journal-title":"Hepatology"},{"key":"BFsrep09114_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fnins.2013.00016","volume":"7","author":"A Panossian","year":"2013","unstructured":"Panossian, A. et al. Synergy and Antagonism of Active Constituents of ADAPT-232 on Transcriptional Level of Metabolic Regulation of Isolated Neuroglial Cells. Front Neurosci 7, 16 (2013).","journal-title":"Front Neurosci"},{"key":"BFsrep09114_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1211\/jpp.60.3.0017","volume":"60","author":"SY Pan","year":"2008","unstructured":"Pan, S. Y. et al. Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice. J Pharm Pharmacol 60, 399\u2013403 (2008).","journal-title":"J Pharm Pharmacol"},{"key":"BFsrep09114_CR18","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.25762","volume":"55","author":"N Chalasani","year":"2012","unstructured":"Chalasani, N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology and the American Gastroenterological Association. Hepatology 55, 2005\u20132023 (2012).","journal-title":"Hepatology"},{"key":"BFsrep09114_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1124\/pr.108.00001","volume":"60","author":"N Anderson","year":"2008","unstructured":"Anderson, N. & Borlak, J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 60, 311\u2013357 (2008).","journal-title":"Pharmacol Rev"},{"key":"BFsrep09114_CR20","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1021\/pr3010327","volume":"12","author":"HY Kwan","year":"2013","unstructured":"Kwan, H. Y. et al. Lipidomics identification of metabolic biomarkers in chemically induced hypertriglyceridemic mice. J Proteome Res 12, 1387\u20131398 (2013).","journal-title":"J Proteome Res"},{"key":"BFsrep09114_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ejphar.2006.03.001","volume":"537","author":"SY Pan","year":"2006","unstructured":"Pan, S. Y. et al. A novel experimental model of acute hypertriglyceridemia induced by schisandrin B. Eur J Pharmacology 537, 200\u2013204 (2006).","journal-title":"Eur J Pharmacology"},{"key":"BFsrep09114_CR22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1021\/pr300965d","volume":"12","author":"Y Tan","year":"2013","unstructured":"Tan, Y. et al. Deciphering the differential toxic responses of Radix aconiti lateralis praeparata in healthy and hydrocortisone-pretreated rats based on serum metabolic profiles. J Proteome Res 12, 513\u2013524 (2013).","journal-title":"J Proteome Res"},{"key":"BFsrep09114_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/hep.20283","volume":"40","author":"AE Feldstein","year":"2004","unstructured":"Feldstein, A. E. et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 40, 185\u2013194 (2004).","journal-title":"Hepatology"},{"key":"BFsrep09114_CR24","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.3748\/wjg.v17.i19.2379","volume":"17","author":"JH Chu","year":"2011","unstructured":"Chu, J. H. et al. Inhibitory effect of schisandrin B on free fatty acid-induced steatosis in L-02 cells. World J Gastroenterol 17, 2379\u20132388 (2011).","journal-title":"World J Gastroenterol"},{"key":"BFsrep09114_CR25","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.1074\/jbc.273.9.5053","volume":"273","author":"JF Lawler Jr","year":"1998","unstructured":"Lawler, J. F., Jr et al. Tumor necrosis factor-alpha stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase. J Biol Chem 273, 5053\u20135059 (1998).","journal-title":"J Biol Chem"},{"key":"BFsrep09114_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1124\/mol.112.084269","volume":"84","author":"R Shimozono","year":"2013","unstructured":"Shimozono, R. et al. Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. Mol Pharmacol 84, 62\u201370 (2013).","journal-title":"Mol Pharmacol"},{"key":"BFsrep09114_CR27","doi-asserted-by":"publisher","first-page":"763257","DOI":"10.1155\/2013\/763257","volume":"2013","author":"SM Shin","year":"2013","unstructured":"Shin, S. M. et al. Role of the Nrf2-ARE pathway in liver diseases. Oxid Med Cell Longev 2013, 763257 (2013).","journal-title":"Oxid Med Cell Longev"},{"key":"BFsrep09114_CR28","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1016\/j.cellsig.2014.07.016","volume":"26","author":"JJ Yang","year":"2014","unstructured":"Yang, J. J. et al. MicroRNA-200a controls Nrf2 activation by target Keap1 in hepatic stellate cell proliferation and fibrosis. Cell Signal 26, 2381\u20132389 (2014).","journal-title":"Cell Signal"},{"key":"BFsrep09114_CR29","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1309\/RTPM1PY6YGBL2G2R","volume":"128","author":"MM Yeh","year":"2007","unstructured":"Yeh, M. M. & Brunt, E. M. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 128, 837\u2013847 (2007).","journal-title":"Am J Clin Pathol"},{"key":"BFsrep09114_CR30","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1038\/emm.2014.10","volume":"46","author":"SW Kim","year":"2014","unstructured":"Kim, S. W. et al. Oleuropein prevents the progression of steatohepatitis to hepatic fibrosis induced by a high-fat diet in mice. Exp Mol Med 46, e92 (2014).","journal-title":"Exp Mol Med"},{"key":"BFsrep09114_CR31","first-page":"674690","volume":"2014","author":"J Wang","year":"2014","unstructured":"Wang, J. et al. BL153 partially prevents high-fat diet induced liver damage probably via inhibition of lipid accumulation, inflammation and oxidative stress. Oxid Med Cell Longev 2014, 674690 (2014).","journal-title":"Oxid Med Cell Longev"},{"key":"BFsrep09114_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1365-2036.2006.02751.x","volume":"23","author":"KM Comar","year":"2006","unstructured":"Comar, K. M. & Sterling, R. K. Review article: Drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 23, 207\u2013215 (2006).","journal-title":"Aliment Pharmacol Ther"},{"key":"BFsrep09114_CR33","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362, 1675\u20131685 (2010).","journal-title":"N Engl J Med"},{"key":"BFsrep09114_CR34","first-page":"285","volume":"40","author":"Y Li","year":"2014","unstructured":"Li, Y. et al. Protective effects of extract fructus Schisandrae chinensis on hepatic injury in experimental hepatic fibrosis rats. Journal of Jilin University 40, 285\u2013288 (2014).","journal-title":"Journal of Jilin University"},{"key":"BFsrep09114_CR35","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0006-2952(96)00517-5","volume":"52","author":"SP IP","year":"1996","unstructured":"IP, S. P. & Ko, K. M. The crucial antioxidant action of schisandrin B in protecting against carbon tetrachloride hepatotoxicity in mice: a comparative study with butylated hydroxytoluene. Biochem Pharmacol 52, 1687\u20131693 (1996).","journal-title":"Biochem Pharmacol"},{"key":"BFsrep09114_CR36","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1248\/bpb.31.602","volume":"31","author":"PY Chiu","year":"2008","unstructured":"Chiu, P. Y. et al. Schisandrin B Enhances Renal Mitochondrial Antioxidant Status, Functional and Structural Integrity and Protects against Gentamicin-Induced Nephrotoxicity in Rats. Biol Pharm Bull 31, 602\u2013605 (2008).","journal-title":"Biol Pharm Bull"},{"key":"BFsrep09114_CR37","doi-asserted-by":"publisher","first-page":"e40480","DOI":"10.1371\/journal.pone.0040480","volume":"7","author":"Z Liu","year":"2012","unstructured":"Liu, Z. et al. Schisandrin B attenuates cancer invasion and metastasis via inhibiting epithelial-mesenchymal transition. PLoS One 7, e40480 (2012).","journal-title":"PLoS One"},{"key":"BFsrep09114_CR38","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1097\/MEG.0b013e3282f9b203","volume":"20","author":"K Morgan","year":"2008","unstructured":"Morgan, K. et al. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 20, 843\u2013854 (2008).","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"BFsrep09114_CR39","first-page":"351","volume":"20","author":"M Kohjima","year":"2007","unstructured":"Kohjima, M. et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 20, 351\u2013358(2007).","journal-title":"Int J Mol Med"},{"key":"BFsrep09114_CR40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.cell.2004.11.043","volume":"120","author":"J Lin","year":"2005","unstructured":"Lin, J. et al. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell 120, 261\u2013273 (2005).","journal-title":"Cell"},{"key":"BFsrep09114_CR41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.plefa.2010.02.016","volume":"82","author":"T Vallim","year":"2010","unstructured":"Vallim, T. & Salter, A. M. Regulation of hepatic gene expression by saturated fatty acids. Prostaglandins Leukot Essent Fatty Acids 82, 211\u2013218 (2010).","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"BFsrep09114_CR42","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1210\/edrv.21.6.0415","volume":"21","author":"BL Wajchenberg","year":"2000","unstructured":"Wajchenberg, B. L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21, 697\u2013738 (2000).","journal-title":"Endocr Rev"},{"key":"BFsrep09114_CR43","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1128\/MCB.15.5.2582","volume":"15","author":"JB Kim","year":"1995","unstructured":"Kim, J. B. et al. Dual DNA binding specificity of ADD1\/SREBP1 controlled by a single amino acid in the basic helix-loop-helix domain. Mol Cell Biol. 15, 2582\u20132588 (1995).","journal-title":"Mol Cell Biol."},{"key":"BFsrep09114_CR44","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1128\/MCB.19.5.3760","volume":"19","author":"M Foretz","year":"1999","unstructured":"Foretz, M. et al. ADD1\/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol Cell Biol. 19, 3760\u20133768 (1999).","journal-title":"Mol Cell Biol."},{"key":"BFsrep09114_CR45","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/0003-9861(88)90013-6","volume":"267","author":"ME Pape","year":"1988","unstructured":"Pape, M. E. et al. Physiological regulation of acetyl-CoA carboxylase gene expression: effects of diet, diabetes and lactation on acetyl-CoA carboxylase mRNA. Arch Biochem Biophys. 267, 104\u2013109 (1988).","journal-title":"Arch Biochem Biophys."},{"key":"BFsrep09114_CR46","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1432-1033.1990.tb15593.x","volume":"190","author":"A Katsurada","year":"1990","unstructured":"Katsurada, A. et al. Effects of nutrients and hormones on transcriptional and post-transcriptional regulation of acetyl-CoA carboxylase in rat liver. Eur J Biochem. 190, 435\u2013441 (1990).","journal-title":"Eur J Biochem."},{"key":"BFsrep09114_CR47","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.bbalip.2011.09.017","volume":"1821","author":"PL Jensen-Urstad Anne","year":"2012","unstructured":"Jensen-Urstad Anne, P. L. & Semenkovich, C. F. Fatty acid synthase and liver triglyceride metabolism: housekeeper or messenger. Biochim Biophys Acta 1821, 747\u2013753 (2012).","journal-title":"Biochim Biophys Acta"},{"key":"BFsrep09114_CR48","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00210-011-0634-x","volume":"383","author":"SY Pan","year":"2011","unstructured":"Pan, S. Y. et al. Effective kinetics of schisandrin B on serum\/hepatic triglyceride and total cholesterol levels in mice with and without the influence of fenofibrate. Naunyn-Schmied Arch Pharmacol 383, 585\u2013591 (2011).","journal-title":"Naunyn-Schmied Arch Pharmacol"},{"key":"BFsrep09114_CR49","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1177\/0192623308323920","volume":"36","author":"S Nishikawa","year":"2008","unstructured":"Nishikawa, S. et al. The effect of fasting on hepatic lipid accumulation and transcriptional regulation of lipid metabolism differs between C57BL\/6J and BALB\/cA mice fed a high-fat diet. Toxicol Pathol 36, 850\u2013857 (2008).","journal-title":"Toxicol Pathol"},{"key":"BFsrep09114_CR50","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.bbrc.2006.03.155","volume":"344","author":"RY Li","year":"2006","unstructured":"Li, R. Y. et al. Effect of short-term and long-term fasting on transcriptional regulation of metabolic genes in rat tissues. Biochem Biophys Res Commun 344, 562\u2013570 (2006).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep09114_CR51","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0022-2275(20)41268-4","volume":"19","author":"JM Amatruda","year":"1978","unstructured":"Amatruda, J. M. et al. [14C]palmitate uptake in isolated rat liver mitochondria: effects of fasting, diabetes mellitus and inhibitors of carnitine acyltransferase. J Lipid Res 19, 688\u2013694 (1978).","journal-title":"J Lipid Res"},{"key":"BFsrep09114_CR52","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.freeradbiomed.2012.08.006","volume":"53","author":"R Checker","year":"2012","unstructured":"Checker, R. et al. Schisandrin B exhibits anti-inflammatory activity through modulation of the redox-sensitive transcription factors Nrf2 and NF-\u03baB. Free Radic Biol Med. 53, 1421\u20131430 (2012).","journal-title":"Free Radic Biol Med."},{"key":"BFsrep09114_CR53","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1002\/ptr.2826","volume":"23","author":"PY Chiu","year":"2009","unstructured":"Chiu, P. Y. et al. Schisandrin B stereoisomers protect against hypoxia\/reoxygenation-induced apoptosis and associated changes in the Ca(2+)-induced mitochondrial permeability transition and mitochondrial membrane potential in AML12 hepatocytes. Phytother Res 23, 1592\u20131602 (2009).","journal-title":"Phytother Res"},{"key":"BFsrep09114_CR54","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.bcp.2011.11.002","volume":"83","author":"EJ Park","year":"2012","unstructured":"Park, E. J. et al. Schisandrin B suppresses TGF\u03b21 signaling by inhibiting Smad2\/3 and MAPK pathways. Biochem Pharmacol 83, 378\u2013384 (2012).","journal-title":"Biochem Pharmacol"},{"key":"BFsrep09114_CR55","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00428-012-1271-6","volume":"461","author":"S Biesterfeld","year":"2012","unstructured":"Biesterfeld, S. et al. Frozen section diagnosis in donor liver biopsies: observer variation of semiquantitative and quantitative steatosis assessment. Virchows Arch 461, 177\u2013183 (2012).","journal-title":"Virchows Arch"},{"key":"BFsrep09114_CR56","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1194\/jlr.M300235-JLR200","volume":"44","author":"D Letexier","year":"2003","unstructured":"Letexier, D. et al. Comparison of the expression and activity of the lipogenic pathway in human and rat adipose tissue. J Lipid Res 44, 2127\u20132134 (2003).","journal-title":"J Lipid Res"},{"key":"BFsrep09114_CR57","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1042\/bj1640501","volume":"164","author":"YA Baqir","year":"1977","unstructured":"Baqir, Y. A. & Booth, R. A new method for assaying rat liver microsomal 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and its application in a study of the effect of dietary cholesterol on this effect of dietary cholesterol on this enzyme. Biochem J 164, 501\u2013508 (1977).","journal-title":"Biochem J"},{"key":"BFsrep09114_CR58","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1172\/JCI44271","volume":"121","author":"P Seale","year":"2011","unstructured":"Seale, P. et al. Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J Clin Invest 121, 96\u2013105 (2011).","journal-title":"J Clin Invest"},{"key":"BFsrep09114_CR59","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cmet.2011.05.002","volume":"13","author":"M Ahmadian","year":"2011","unstructured":"Ahmadian, M. et al. Desnutrin\/ATGL is regulated by AMPK and is required for a brown adipose phenotype. Cell Metabolism 13, 739\u2013748 (2011).","journal-title":"Cell Metabolism"},{"key":"BFsrep09114_CR60","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jhep.2006.10.019","volume":"46","author":"C Jackel-Cram","year":"2007","unstructured":"Jackel-Cram, C. et al. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol. 46, 999\u20131008 (2007).","journal-title":"J Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep09114","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep09114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep09114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:52:06Z","timestamp":1672966326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep09114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,13]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,8,14]]}},"alternative-id":["BFsrep09114"],"URL":"https:\/\/doi.org\/10.1038\/srep09114","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,13]]},"assertion":[{"value":"28 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9114"}}